See more : PT Habco Trans Maritima Tbk (HATM.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Trean Insurance Group, Inc. (TIG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trean Insurance Group, Inc., a leading company in the Insurance – Specialty industry within the Financial Services sector.
You may be interested
- Shoprite Holdings Limited (SRGHY) Income Statement Analysis – Financial Results
- Mahindra Logistics Limited (MAHLOG.NS) Income Statement Analysis – Financial Results
- H&R GmbH & Co. KGaA (2HRA.DE) Income Statement Analysis – Financial Results
- Lion Corporation (LIOPF) Income Statement Analysis – Financial Results
- Naigai Tec Corporation (3374.T) Income Statement Analysis – Financial Results
Trean Insurance Group, Inc. (TIG)
About Trean Insurance Group, Inc.
Trean Insurance Group, Inc. underwrites specialty casualty insurance products in the United States. The company underwrites business, predominantly workers' compensation, accident and health, and medical professional liability products. It also offers a variety of services, including issuing carrier, claims administration, and reinsurance brokerage services. The company offers its products through program partners and managing general agents. Trean Insurance Group, Inc. was founded in 1996 and is based in Wayzata, Minnesota.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 12.02M | 219.92M | 132.26M | 102.52M | 78.50M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.02M | 219.92M | 132.26M | 102.52M | 78.50M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 52.81M | 50.22M | 39.17M | 21.01M | 15.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -27.00K |
| SG&A | 52.81M | 50.22M | 39.17M | 21.01M | 15.68M |
| Other Expenses | 294.04M | -245.36M | -85.94M | -85.16M | -16.32M |
| Operating Expenses | 380.25M | -195.14M | -46.77M | -64.16M | -639.00K |
| Cost & Expenses | 380.15M | 195.14M | 37.00M | 67.71M | 52.35M |
| Interest Income | 192.00K | 4.00K | 25.00K | 127.00K | 90.00K |
| Interest Expense | 3.27M | 1.69M | 1.92M | 2.17M | 1.56M |
| Depreciation & Amortization | 6.00M | 5.83M | 2.57M | 876.00K | 497.00K |
| EBITDA | -54.79M | 30.61M | 88.06M | 39.24M | 27.12M |
| EBITDA Ratio | -455.70% | 13.92% | 66.58% | 38.27% | 34.55% |
| Operating Income | -60.79M | 24.78M | 85.49M | 38.36M | 26.63M |
| Operating Income Ratio | -505.58% | 11.27% | 64.64% | 37.42% | 33.92% |
| Total Other Income/Expenses | -4.09M | 0.00 | 9.77M | -46.71M | -475.00K |
| Income Before Tax | -64.88M | 24.78M | 95.26M | 34.80M | 26.15M |
| Income Before Tax Ratio | -539.60% | 11.27% | 72.03% | 33.95% | 33.31% |
| Income Tax Expense | 1.07M | 5.45M | 6.83M | 7.07M | 5.55M |
| Net Income | -65.96M | 19.33M | 90.77M | 31.29M | 19.52M |
| Net Income Ratio | -548.53% | 8.79% | 68.63% | 30.52% | 24.87% |
| EPS | -1.29 | 0.38 | 2.02 | 0.75 | 0.38 |
| EPS Diluted | -1.29 | 0.38 | 2.02 | 0.75 | 0.38 |
| Weighted Avg Shares Out | 51.20M | 51.16M | 43.74M | 37.39M | 51.14M |
| Weighted Avg Shares Out (Dil) | 51.20M | 51.17M | 43.74M | 37.39M | 51.14M |
Takeda en TiGenix maken resultaten bekend van tweede acceptatieperiode voor het vrijwillige en voorwaardelijke openbare overnamebod van TiGenix en aanvang van de vereenvoudigde uitkoop en de intentie de ADS’en uit Nasdaq te schrappen...
Osaka, Japan en Leuven, België--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502): Takeda en TiGenix maken resultaten bekend van tweede acceptatieperiode voor het vrijwillige en voorwaardelijke openbare overnamebod van TiGenix en aanvang van de vereenvoudigde uitkoop en de intentie de ADS’en...
Takeda y TiGenix anuncian los resultados del segundo periodo de aceptación de la oferta pública de adquisición voluntaria y condicional con respecto a TiGenix, el comienzo de la venta forzosa simplificada y su intención de borrar las ADS...
Osaka, Japón y Lovaina, Bélgica--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502): Takeda y TiGenix anuncian los resultados del segundo periodo de aceptación de la oferta pública de adquisición voluntaria y condicional con respecto a TiGenix, el comienzo de la venta...
Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq...
OSAKA, Japan & LEUVEN, Belgium--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502): Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to...
Takeda et TiGenix annoncent les résultats de la première période d’acceptation pour l’offre publique d’acquisition volontaire et conditionnelle de TiGenix et le début de la deuxième période d’acceptation.
Osaka, Japon et Louvain, Belgique--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE : 4502) (« Takeda ») et TiGenix NV (Euronext Brussels et Nasdaq : TIG) (« TiGenix ») ont annoncé aujourd’hui les résultats de la première période d’acceptation de l’Offre en...
Takeda y TiGenix anuncian los resultados del primer periodo de aceptación de la oferta pública de adquisición voluntaria y condicional de TiGenix y el comienzo del segundo periodo de aceptación
Osaka, Japón y Lovaina, Bélgica--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) y TiGenix NV (Euronext Brussels y Nasdaq: TIG) (“TiGenix”) han anunciado hoy los resultados del primer periodo de aceptación de la oferta pública previamente anunciada de Takeda (la...
Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period
OSAKA, Japan & LEUVEN, Belgium--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced the results of the first acceptance period of Takeda’s previously announced tender offer (the “Bid”) in cash...
Takeda en TiGenix maken resultaten bekend van eerste acceptatieperiode voor het vrijwillige en voorwaardelijke openbare overnamebod van TiGenix en de aanvang van de tweede acceptatieperiode
Osaka, Japan en Leuven, België--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (‘Takeda’) en TiGenix NV (Euronext Brussel en Nasdaq: TIG) (‘TiGenix’) hebben vandaag de resultaten bekendgemaakt van de eerste acceptatieperiode van Takeda's eerder aangekondigde overnamebod (het ‘Bod’) in contanten voor...
Takeda Announces Information Related to its Pending Voluntary and Conditional Public Takeover Bid for Outstanding Shares and American Depositary Shares of TiGenix
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced information related to its previously announced and ongoing tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) and American Depositary Shares (“ADSs”) of...
Takeda anuncia información relacionada a su oferta pública de adquisición voluntaria y condicional para las acciones en circulación y las acciones de depósito estadounidenses de TiGenix
OSAKA, Japón--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) anunció información hoy relacionada a la oferta pública de adquisición previamente anunciada y actual (la “Oferta”) en efectivo de todas las acciones ordinarias en circulación (“Acciones Ordinarias”), autorizaciones de adquisición (“Autorizaciones”)...
Takeda geeft melding van informatie over het lopende vrijwillige en voorwaardelijke openbare overnamebod voor uitstaande aandelen, warrants en Amerikaanse Depositary Shares van TiGenix
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) heeft vandaag informatie bekendgemaakt aangaande de eerder aangekondigde en lopende tenderaanbieding (het “Bod”) in contanten voor alle uitstaande gewone aandelen (“Gewone Aandelen”), warrants (“Warrants”) en American Depositary Shares (“ADS'en”) van TiGenix...
Source: https://incomestatements.info
Category: Stock Reports